Drug intelligence / Profile preview

Buxueyimu Keli

Development stage: Unknown
Lead developer: Zhuzhou Qianjin Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

Buxueyimu Keli is a Traditional Chinese Medicine (TCM) formulation, presented in granule form, currently undergoing clinical investigation for the treatment of postpartum conditions. These conditions include postpartum anemia, lochia, abdominal pain, and issues related to uterine recovery. The name 'Bu-Xue Yi-Mu' suggests its traditional therapeutic focus on 'tonifying blood' and incorporating ingredients like Motherwort (Leonurus japonicus), which is historically used for gynecological health and promoting uterine contraction and blood circulation.

Other names: BuxueyimuBu-Xue Yi-Mu particles补血益母颗粒

Beyond the preview

Go deeper on Buxueyimu Keli.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Buxueyimu Keli.

Explore the full profile